{"id":74974,"date":"2026-08-17T13:21:25","date_gmt":"2026-08-17T05:21:25","guid":{"rendered":"https:\/\/flcube.com\/?p=74974"},"modified":"2026-08-17T13:21:26","modified_gmt":"2026-08-17T05:21:26","slug":"shanghai-ark-biopharmaceutical-wins-fda-clearance-for-ziresovir-phase-ii-trials-in-severe-pediatric-rsv","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74974","title":{"rendered":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Ark Biopharmaceutical Co., Ltd.<\/strong> announced that the <strong>US Food and Drug Administration (FDA)<\/strong> has recently approved its innovative <strong>anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529)<\/strong>, to conduct <strong>Phase II clinical trials in the United States<\/strong> for the treatment of <strong>severe RSV infection in infants and young children<\/strong>, including <strong>pediatric intensive care unit (PICU)<\/strong> hospitalized patients.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (US)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase II clinical trial approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ziresovir (AK0529), anti\u2011RSV antiviral<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Severe RSV infection in infants and young children, including PICU\u2011hospitalized patients<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of US Phase II studies in severe pediatric RSV<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Ziresovir (AK0529)<\/strong>, an innovative <strong>targeted RSV\u2011specific antiviral drug<\/strong><\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Status:<\/strong> The <strong>world&#8217;s first<\/strong> RSV\u2011specific antiviral to successfully complete <strong>Phase III clinical trials with positive results<\/strong><\/li>\n\n\n\n<li><strong>Indication Focus:<\/strong> Severe RSV infection in the highest\u2011risk pediatric population, including PICU\u2011hospitalized patients<\/li>\n\n\n\n<li><strong>Global Recognition:<\/strong> In 2025, ziresovir was included in the <strong>World Health Organization (WHO)<\/strong> priority list of pediatric medicines for RSV<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-program-china\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III Program (China)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Ziresovir)<\/th><\/tr><\/thead><tbody><tr><td><strong>Viral Load<\/strong><\/td><td>Significantly reduced in pediatric patients<\/td><\/tr><tr><td><strong>Respiratory Symptoms<\/strong><\/td><td>Accelerated relief observed<\/td><\/tr><tr><td><strong>Recurrent Wheezing &amp; Asthma Risk (24\u2011month follow\u2011up)<\/strong><\/td><td>Significantly lowered<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable safety profile demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Prior Phase III clinical studies completed in China demonstrated that <strong>ziresovir<\/strong> significantly reduced viral load in pediatric patients, accelerated the relief of respiratory symptoms, and significantly lowered the risk of <strong>recurrent wheezing and asthma<\/strong> over a 24\u2011month follow\u2011up, while demonstrating a favorable safety profile. The long\u2011term reduction in respiratory sequelae is of particular importance in severe RSV disease, where recurrent wheezing and subsequent asthma remain major clinical concerns.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Unmet Need:<\/strong> RSV is the leading viral cause of infant hospitalization worldwide, and severe cases requiring PICU care currently lack approved targeted antivirals \u2014 positioning <strong>ziresovir<\/strong> in a segment with substantial unmet medical need.<\/li>\n\n\n\n<li><strong>Differentiated Evidence Base:<\/strong> As the first RSV\u2011specific antiviral with positive Phase III results \u2014 including 24\u2011month follow\u2011up data showing reduced wheezing and asthma risk \u2014 <strong>ziresovir<\/strong> carries clinical evidence no competing candidate has yet matched.<\/li>\n\n\n\n<li><strong>Global Expansion Strategy:<\/strong> The FDA approval extends <strong>Shanghai Ark Biopharmaceutical&#8217;s<\/strong> development program beyond China into the US market, with a PICU\u2011focused indication that could support differentiated positioning in severe pediatric RSV.<\/li>\n\n\n\n<li><strong>WHO Endorsement:<\/strong> Inclusion on the <strong>WHO<\/strong> priority list of pediatric medicines for RSV underscores the drug&#8217;s global public health relevance and may support regulatory and access pathways in additional markets.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial conduct, regulatory outcomes, and commercial potential for ziresovir (AK0529). Actual results may differ due to risks including Phase II trial results, regulatory decisions, and competitive dynamics in the RSV therapeutic market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1443,62],"class_list":["post-74974","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74974\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV\" \/>\n<meta property=\"og:description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74974\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T05:21:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T05:21:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV\",\"datePublished\":\"2026-08-17T05:21:25+00:00\",\"dateModified\":\"2026-08-17T05:21:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974\"},\"wordCount\":481,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74974#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74974\",\"name\":\"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T05:21:25+00:00\",\"dateModified\":\"2026-08-17T05:21:26+00:00\",\"description\":\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74974\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74974#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74974","og_locale":"en_US","og_type":"article","og_title":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV","og_description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.","og_url":"https:\/\/flcube.com\/?p=74974","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T05:21:25+00:00","article_modified_time":"2026-08-17T05:21:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74974#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74974"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV","datePublished":"2026-08-17T05:21:25+00:00","dateModified":"2026-08-17T05:21:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74974"},"wordCount":481,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74974#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74974","url":"https:\/\/flcube.com\/?p=74974","name":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T05:21:25+00:00","dateModified":"2026-08-17T05:21:26+00:00","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has recently approved its innovative anti\u2011respiratory syncytial virus (RSV) drug, ziresovir (AK0529), to conduct Phase II clinical trials in the United States for the treatment of severe RSV infection in infants and young children, including pediatric intensive care unit (PICU) hospitalized patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74974#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74974"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74974#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74974"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74974\/revisions"}],"predecessor-version":[{"id":74976,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74974\/revisions\/74976"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}